Searchable abstracts of presentations at key conferences in endocrinology

Endocrine Abstracts

Published by BioScientifica

Page 1 of about 7 results

ea0090ep721 | Pituitary and Neuroendocrinology | ECE2023

An international, simulated-use study assessing nurses’ preferences between two lanreotide syringes (Somatuline Autogel vs Pharmathen) for treatment of neuroendocrine tumours (NETs) and/or acromegaly: PRESTO 3

Ferone Diego , Martin Wendy , Williams Jessica , Houchard Aude , Pommie Christelle , Ribeiro-Oliveira Antonio , Grossman Ashley B

Introduction/Background: Patients with NETs and acromegaly are commonly treated with somatostatin analogues (SSAs), such as octreotide and lanreotide depot formulations. The Pharmathen syringe is now available in several European countries and the USA for lanreotide depot injection. When using SSAs, confidence in and ease of use with syringes is important for decision-making in long-term therapy.Aims: PRESTO 3 compared nurses’ preference for the Som...
4 shares

ea0068p9 | Abstracts | UKINETS2019

Gastric neuroendocrine neoplasms: clinical management and outcomes in a cohort of 54 patients

Victor Alexandra , Ramage John Keith , Cope Jack , Maclean Rory , Hayee Bu , Martin Wendy , Cananea Elmie , Clement Dominique , Srirajaskanthan Raj

Introduction: Gastric NENs are increasingly being diagnosed at endoscopy. The majority of these are type 1 gastric NEN. However, around 10–20% can be type 3 or type 4 Gastric NENs.Methods: A retrospective review performed of 54 patients with gastric NENs referred to a tertiary centre during 2014 to 2019.Results: Of the 54 cases referred, 45 were type 1 gastric NENs and the 9 were type 3 Gastric NENs. Of the 45 type 1 gastric N...
0 shares

ea0098o6 | Other | NANETS2023

PRESTO 3: An international, simulated-use study assessing preferences of nurses between two lanreotide syringes (Somatuline® Autogel® vs Pharmathen)

Ferone Diego , Martin Wendy , Williams Jessica , Houchard Aude , Pommie Christelle , Mai Truong-Thanh Xuan , Ribeiro-Oliveira Jr. Antonio , Grossman Ashley

Background: Patients with neuroendocrine tumours (NETs) and acromegaly are commonly treated with somatostatin analogs (SSAs), such as octreotide and lanreotide depot formulations. The Pharmathen syringe is now available in several European countries and the USA for lanreotide depot injection. When using SSAs, confidence in and ease of use with syringes are important for decision-making in long-term therapy. The aim of the PRESTO 3 study was to compare nurses’ preference f...
0 shares

ea0096p2 | Section | UKINETS2023

The Global leadership into malnutrition criteria reveals a high percentage of malnutrition which influences overall survival in patients with gastroenteropancreatic neuroendocrine tumours using somatostatin analogues

Clement Dr. Dominique , Monique van Leerdam Prof , Tesselaar Dr. Margot , Cananea Ms. Elmie , Martin Ms. Wendy , Martin Weickert Prof , Sarker Dr. Debashis , John Ramage Prof , Srirajaskanthan Dr. Rajaventhan

Introduction: Patients with neuroendocrine tumours located in the gastroenteropancreatic tract (GEP-NETs) and treatment with somatostatin analogues (SSA’s) are at risk of malnutrition which has been reported previously, based on weight loss or body mass index (BMI) only. Since 2019 The Global leadership into malnutrition (GLIM) criteria exist to diagnose malnutrition, including weight loss, BMI and sarcopenia. These GLIM criteria have not been assessed in...
0 shares

ea0096p3 | Section | UKINETS2023

High prevalence of deficiencies in fat-soluble vitamins, minerals and trace elements but no relation with malnutrition in patients with gastroenteropancreatic neuroendocrine tumours using somatostatin analogue’s

Dominique Clement Dr , Monique van Leerdam Prof , Tesselaar Dr. Margot , Cananea Ms. Elmie , Martin Ms. Wendy , Martin Weickert Prof , Brown Dr. Sarah , John Ramage Prof , Srirajaskanthan Dr. Rajaventhan

Introduction: Since 2019 the Global Leadership Into Malnutrition (GLIM) criteria exist for diagnosing malnutrition. Patients with gastoenteropancreatic (GEP) neuroendocrine tumours (NETs) using somatostatin analogue’s (SSA’s) are at risk of malnutrition. Deficiencies in fat-soluble vitamins, minerals and trace elements are not part of the GLIM criteria but frequently reported in patients with GEP-NETs using SSA’s. The relationship between malnut...
1 shares

ea0060p18 | (1) | UKINETS2018

The impact of 68Ga-based PET-CT scanning on the management of patients with sporadic pancreatic neuroendocrine tumours (pNETs)

Cuthbertson Daniel , Barriuso Jorge , Pizanais Michail , Jaffa Matthew , Lamarca Angela , Vivian Gillian , Halloran Tom , Westwood Tom , Prachalias Andreas , O'Reilly Derek , Weismann Hulya , Martin Wendy , Vinjamuri Sobhan , Pritchard D Mark , Hubner Richard , Srirajaskanthan Raj , Ramage John , Raraty Mike , Ganeh Paula , Fenwick Steve , Valle Juan , Yip Vincent

Background: Pancreatic neuroendocrine tumours (panNETs) are rare tumours (prevalence 4/100,000). Diagnosis and staging of panNETs requires biochemical screening, cross-sectional imaging (with CT/MRI), endoscopic ultrasound (EUS) and where available, functional imaging using 68Ga-labelled synthetic octreotide analogues using PET-CT due to its reported higher sensitivity and specificity.Methods: A retrospective, electronic case note study was ca...
0 shares

ea0060p30 | (1) | UKINETS2018

The impact of 68Ga-based PET-CT scanning on the management of patients with familial pancreatic neuroendocrine tumours (panNETs)

Cuthbertson Daniel , Barriuso Jorge , Pizanias Michail , Jaffa Matthew , Nuttall Christina , Vivian Gillian , Halloran Tom , Westwood Tom , Prachalias Andreas , Lalloo Fiona , Weismann Hulya , Martin Wendy , Vinjamuri Sobhan , Mark Pritchard D. , Fenwick Steve , Ganeh Paula , Raraty Mike , McNamara Mairead , Srirajaskanthan Raj , Ramage John , Manoharan Prakash , Yip Vincent

Background: Pancreatic neuroendocrine tumours (panNETs) may arise as part of an underlying genetic condition such as multiple endocrine neoplasia type 1 (MEN type 1). The value of functional imaging using 68Ga-labelled synthetic octreotide analogues using PET-CT has not been extensively evaluated in patients with MEN1 to determine its value.Methods: We investigated the effect of 68Ga-based PET-CT imaging on patient management in pat...
0 shares

Published by BioScientifica

Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 | Privacy policy | Cookie settings

BiosciAbstracts

Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.

Find out more